menu
    • menu
    [{"orgOrder":0,"company":"Merck Group","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ EMD Serono","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ EMD Serono"},{"orgOrder":0,"company":"Merck Group","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ EMD Serono","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ EMD Serono"},{"orgOrder":0,"company":"Merck Group","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ EMD Serono","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ EMD Serono"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Merck & Co"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Merck & Co"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Merck Group"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Evobrutinib

    Menu

    Evobrutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : EMD Serono

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Initiation of New Patients on Evobrutinib Paused in the U.S.; Fully Enrolled Phase III Evobrutinib Studies Con...

                            Details : M2951 (evobrutinib) is an oral, CNS-penetrating, highly selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development as a potential treatment for relapsing multiple sclerosis (RMS).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 04, 2023

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : EMD Serono

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Scle...

                            Details : M2951 (evobrutinib) is a BTK inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of relapsing multiple sclerosis via oral tablet.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 12, 2023

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Merck Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People wit...

                            Details : M2951 (evobrutinib) is an oral, highly selective CNS-penetrant inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development as a potential treatment for relapsing multiple sclerosis (RMS).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 26, 2022

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            EMD Serono

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            EMD Serono

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evobrutinib,Interferon Beta 1A

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EMD Serono Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022

                            Details : New Phase II data show evobrutinib sustained low annualized relapse rates (ARRs) and had no new safety signals at 2.5 years – the longest follow-up of any Bruton’s tyrosine kinase inhibitor in multiple sclerosis (MS).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : Evobrutinib,Interferon Beta 1A

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DDI Study of Evobrutinib and Carbamazepine

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 21, 2022

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 18, 2022

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction i...

                            Details : Evobrutinib (M2951) is investigational used as a treatment for multiple sclerosis. It is oral, highly selective inhibitor of Bruton’s tyrosine kinase (BTK) which is important in the development and functioning of various immune cells including B lympho...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 14, 2021

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 01, 2021

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            EMD Serono

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            EMD Serono

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EMD Serono's Evobrutinib, First and Only BTK Inhibitor to Reduce a Key Biomarker of Neuronal Damage and Inflam...

                            Details : Data presented at AAN shows investigational evobrutinib significantly reduced blood neurofilament light chain (NfL) levels, which may predict future brain atrophy and disease progression, in patients with relapsing MS.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 16, 2021

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            EMD Serono

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            EMD Serono

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021

                            Details : Investigational evobrutinib is the first Bruton’s tyrosine kinase (BTK) inhibitor to complete Phase III clinical trial enrollment in relapsing multiple sclerosis (RMS).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 10, 2021

                            Lead Product(s) : Evobrutinib

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth